Ann Beliën established Rejuvenate Biomed in 2017, where she currently functions as founder and CEO. Ann has over 17 years of experience in drug development from bench to market, which she acquired at Johnson & Johnson throughout multiple international assignments (US, NL, BE). She developed from scientist to operational and strategic roles (oncology, neurology, infectious diseases) including external and open innovation (therapeutics and prevention). She joined Johnson & Johnson in 2000, after a postdoc at ETH, Zürich, Switzerland. She holds a PhD from the University of Irchel, Zürich, Switzerland and a master’s degree from the Free University of Brussels (VUB), Belgium.